The pharmaceutical industry has been witnessing a quick turnaround as the revenues are touching new heights. More and more companies are diverting their focus towards developing medicines to cure life-threatening diseases. In this series, Invivo Therapeutics Holdings Corp (OTCMKTS:NVIV) has also hinted some changes to make the best use of the current market conditions. As per the reports, it has announced that Lorianne Masuoka, MD will be its new Chief Medical Officer.
Background Of NEW CMO:
Lorianne will take over the charge from Invivo’s interim Chief Medical Officer Lou Vaickus, MD. Vaickus comes with a huge experience in the life science industry. He previously founded akta Pharmaceutical Development LLC, which specialized in issues related to life science. Along with Invivo’s CMO’s post, he also worked as the President of his own company.
When it comes to Dr. Lorianne, she worked at Cubist Pharmaceuticals before joining Invivo as the Chief Medical Officer and Senior Vice President of the company. She worked there from July 2013 to January 2015 and managed a team of over 150 employees in the areas of drug safety, clinical research, and clinical operations, biostatistics and data management. She had worked at Nektar Therapeutics before joining Cubist. Lorianne was the CMO and Senior Vice President of the company from August 2008 to August 2011. Throughout her tenure, Dr. Lorianne worked as one of the most sought after leaders and industry experts. Her subject matter knowledge always gave her edge over others.
She comes with a medical degree called residency in neurology from the University of California, which is considered as one of the most prominent institutes in the world. Upon completion of her graduation, she went on to pursue epilepsy fellowship at the well-known Yale University. Apart from these degrees, she also has a board certification from none other than the American Board of Psychiatry and Neurology.